Surmodics, Inc. (SRDX) Analysts See $-0.01 EPS

April 16, 2018 - By Rusty Cady

Surmodics, Inc. (NASDAQ:SRDX) LogoInvestors sentiment decreased to 0.69 in 2017 Q4. Its down 0.25, from 0.94 in 2017Q3. It fall, as 11 investors sold Surmodics, Inc. shares while 44 reduced holdings. 12 funds opened positions while 26 raised stakes. 11.07 million shares or 0.98% less from 11.18 million shares in 2017Q3 were reported.
State Board Of Administration Of Florida Retirement Systems accumulated 0% or 22,922 shares. The Pennsylvania-based Sei Invests has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Strs Ohio owns 23,800 shares for 0% of their portfolio. Ny State Common Retirement Fund holds 15,300 shares or 0% of its portfolio. Gabelli Funds Ltd Liability Corporation has invested 0.02% in Surmodics, Inc. (NASDAQ:SRDX). Meeder Asset Inc owns 34 shares. Alliancebernstein L P has 28,921 shares. Citigroup Inc holds 6,125 shares. 2,627 were accumulated by State Of Alaska Department Of Revenue. Invesco Limited reported 44,719 shares. Moreover, Ameritas Inv Partners has 0% invested in Surmodics, Inc. (NASDAQ:SRDX). Mason Street Ltd Llc stated it has 0% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX). Pnc Svcs Gru has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Geode Mgmt owns 132,965 shares or 0% of their US portfolio. Sector Pension Inv Board invested in 0% or 8,380 shares.

Since December 11, 2017, it had 0 insider purchases, and 2 selling transactions for $63,711 activity.

Analysts expect Surmodics, Inc. (NASDAQ:SRDX) to report $-0.01 EPS on April, 26.They anticipate $0.06 EPS change or 120.00 % from last quarter’s $0.05 EPS. After having $0.10 EPS previously, Surmodics, Inc.’s analysts see -110.00 % EPS growth. The stock decreased 1.03% or $0.4 during the last trading session, reaching $38.6. About 14,359 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 61.37% since April 16, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

Among 2 analysts covering Surmodics (NASDAQ:SRDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Surmodics had 2 analyst reports since February 28, 2018 according to SRatingsIntel. The company was upgraded on Wednesday, February 28 by Barrington Research.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. The company has market cap of $509.39 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 19300 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.